Loading...

Euroespes

BME:EEP
Snowflake Description

Moderate growth potential and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EEP
BME
€7M
Market Cap
  1. Home
  2. ES
  3. Pharmaceuticals & Biotech
Company description

Euroespes, S.A., a medical center, provides medical services for the prevention, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. The last earnings update was 173 days ago. More info.


Add to Portfolio Compare Print
  • Euroespes has significant price volatility in the past 3 months.
EEP Share Price and Events
7 Day Returns
17.4%
BME:EEP
-1.8%
Europe Life Sciences
1.2%
ES Market
1 Year Returns
-41.3%
BME:EEP
14.7%
Europe Life Sciences
-1.9%
ES Market
EEP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Euroespes (EEP) 17.4% -9.9% -16.9% -41.3% -41.3% -41.8%
Europe Life Sciences -1.8% -1.1% 9.7% 14.7% 65.1% 176.3%
ES Market 1.2% 2% 5.9% -1.9% 6.3% -9.4%
1 Year Return vs Industry and Market
  • EEP underperformed the Life Sciences industry which returned 14.7% over the past year.
  • EEP underperformed the Market in Spain which returned -1.9% over the past year.
Price Volatility
EEP
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Euroespes undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Euroespes. This is due to cash flow or dividend data being unavailable. The share price is €0.64.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Euroespes's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Euroespes's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BME:EEP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €0.00
BME:EEP Share Price ** BME (2019-04-18) in EUR €0.64
Europe Life Sciences Industry PE Ratio Median Figure of 17 Publicly-Listed Life Sciences Companies 37.35x
Spain Market PE Ratio Median Figure of 132 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Euroespes.

BME:EEP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= BME:EEP Share Price ÷ EPS (both in EUR)

= 0.64 ÷ 0.00

704.85x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Euroespes is overvalued based on earnings compared to the Europe Life Sciences industry average.
  • Euroespes is overvalued based on earnings compared to the Spain market.
Price based on expected Growth
Does Euroespes's expected growth come at a high price?
Raw Data
BME:EEP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 704.85x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
33.2%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 10 Publicly-Listed Life Sciences Companies 2.16x
Spain Market PEG Ratio Median Figure of 75 Publicly-Listed Companies 1.35x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Euroespes, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Euroespes's assets?
Raw Data
BME:EEP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.78
BME:EEP Share Price * BME (2019-04-18) in EUR €0.64
Europe Life Sciences Industry PB Ratio Median Figure of 37 Publicly-Listed Life Sciences Companies 3.33x
Spain Market PB Ratio Median Figure of 180 Publicly-Listed Companies 1.84x
BME:EEP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= BME:EEP Share Price ÷ Book Value per Share (both in EUR)

= 0.64 ÷ 0.78

0.82x

* Primary Listing of Euroespes.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Euroespes is good value based on assets compared to the Europe Life Sciences industry average.
X
Value checks
We assess Euroespes's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Euroespes has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Euroespes expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

  • No analysts cover Euroespes, future earnings growth has been estimated based on fundamentals.
The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
33.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Euroespes expected to grow at an attractive rate?
  • Euroespes's earnings growth is expected to exceed the low risk savings rate of 1.5%.
Growth vs Market Checks
  • Euroespes's earnings growth is expected to exceed the Spain market average.
  • Unable to compare Euroespes's revenue growth to the Spain market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
BME:EEP Future Growth Rates Data Sources
Data Point Source Value (per year)
BME:EEP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts 33.2%
Europe Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 14.1%
Europe Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 8.7%
Spain Market Earnings Growth Rate Market Cap Weighted Average 9.8%
Spain Market Revenue Growth Rate Market Cap Weighted Average 5.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BME:EEP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BME:EEP Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 3 1 0
2018-03-31 3 1 0
2017-12-31 3 1 0
2017-09-30 4 1 0
2017-06-30 4 1 0
2017-03-31 4 1 0
2016-12-31 3 0 0
2016-06-30 3 1 0
2016-03-31 3 1 0
2015-12-31 3 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Euroespes's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Euroespes is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BME:EEP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Euroespes Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BME:EEP Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 0.00
2018-03-31 0.01
2017-12-31 0.02
2017-09-30 0.05
2017-06-30 0.08
2017-03-31 0.07
2016-12-31 0.07
2016-06-30 0.05
2016-03-31 0.05
2015-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Euroespes will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Euroespes's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Euroespes has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Euroespes performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Euroespes's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Euroespes's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • Euroespes's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Euroespes's 1-year earnings growth is negative, it can't be compared to the Europe Life Sciences industry average.
Earnings and Revenue History
Euroespes's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Euroespes Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BME:EEP Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 3.30 0.00
2018-03-31 3.36 0.06
2017-12-31 3.42 0.11
2017-09-30 3.54 0.26 0.00
2017-06-30 3.65 0.42 0.00
2017-03-31 3.54 0.38 0.00
2016-12-31 3.43 0.34
2016-06-30 3.06 0.22 0.00
2016-03-31 2.96 0.21 0.00
2015-12-31 2.86 0.21
2015-06-30 2.50 0.18 0.00
2015-03-31 2.50 0.18 0.00
2014-12-31 2.50 0.18
2012-12-31 2.70 -0.64
2012-09-30 2.87 -0.34 -0.01
2012-06-30 3.03 -0.04 -0.03

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Euroespes has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Euroespes used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • Euroespes's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Euroespes's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Euroespes has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Euroespes's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Euroespes's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Euroespes's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Euroespes's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Euroespes's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Euroespes Company Filings, last reported 9 months ago.

BME:EEP Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 4.58 4.24 0.20
2018-03-31 4.58 4.24 0.20
2017-12-31 4.57 3.89 0.03
2017-09-30 4.57 3.89 0.03
2017-06-30 4.43 4.01 0.06
2017-03-31 4.43 4.01 0.06
2016-12-31 4.26 3.82 0.08
2016-06-30 3.09 2.28 0.16
2016-03-31 3.09 2.28 0.16
2015-12-31 3.08 1.89 0.10
2015-06-30
2015-03-31 2.75 1.66 0.19
2014-12-31 2.75 1.66 0.19
2012-12-31 3.26 0.39 0.20
2012-09-30 3.26 0.39 0.20
2012-06-30 3.85 0.45 0.44
  • Euroespes's level of debt (92.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (22.4% vs 92.6% today).
  • Debt is not well covered by operating cash flow (13.8%, less than 20% of total debt).
  • Interest payments on debt are not well covered by earnings (EBIT is 0.4x annual interest expense, ideally 3x coverage).
X
Financial health checks
We assess Euroespes's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Euroespes has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Euroespes's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Euroespes dividends.
If you bought €2,000 of Euroespes shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Euroespes's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Euroespes's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BME:EEP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 0.9%
Spain Market Average Dividend Yield Market Cap Weighted Average of 75 Stocks 4.3%
Spain Minimum Threshold Dividend Yield 10th Percentile 1.1%
Spain Bottom 25% Dividend Yield 25th Percentile 1.9%
Spain Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Euroespes has not reported any payouts.
  • Unable to verify if Euroespes's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Euroespes's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Euroespes has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Euroespes's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Euroespes afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Euroespes has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Euroespes's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • Euroespes has no CEO, or we have no data on them.
Management Team

Ramón García

TITLE
Chairman of the Board of Directors

José Antonio Romero

TITLE
Executive Director
Board of Directors

Ramón García

TITLE
Chairman of the Board of Directors

José Antonio Romero

TITLE
Executive Director

Valentín Llorente

TITLE
Director

Ángel Alcalde

TITLE
Director

Pablo de Linera Granda

TITLE
Independent Director

Juan de Sanmamed Sampedro

TITLE
Director

José Pablo Pérez

TITLE
Director

Juan Carlos Villa

TITLE
Director

Aquilino Puga

TITLE
Independent Director
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Euroespes's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Euroespes has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Share Price Volatility Should You Expect For Euroespes, S.A. (BME:EEP)?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market.

Simply Wall St -

Does Euroespes SA's (BME:EEP) P/E Ratio Signal A Buying Opportunity?

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … To keep it practical, we'll show how Euroespes SA's (BME:EEP) P/E ratio could help you assess the value on offer. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

Will EuroEspes SA. (BME:EEP) Continue To Underperform Its Industry?

Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of EuroEspes’s equity capital deployed. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity BME:EEP Last Perf May 22nd 18 Essentially, profit margin shows how much money the company makes after paying for all its expenses. … And finally, financial leverage is simply how much of assets are funded by equity, which exhibits how sustainable the company’s capital structure is.

Simply Wall St -

Should You Have EuroEspes SA.'s (BME:EEP) In Your Portfolio?

Generally, an investor should consider two types of risk that impact the market value of EEP. … A popular measure of market risk for a stock is its beta, and the market as a whole represents a beta value of one. … Based on this beta value, EEP appears to be a stock that an investor with a high-beta portfolio would look for to reduce risk exposure to the market.

Simply Wall St -

Is EuroEspes SA. (BME:EEP) A Financially Sound Company?

EEP has built up its total debt levels in the last twelve months, from €2.91M to €3.82M , which is made up of current and long term debt. … Additionally, EEP has produced €451.25K in operating cash flow during the same period of time, leading to an operating cash to total debt ratio of 11.82%, indicating that EEP’s operating cash is not sufficient to cover its debt. … For EEP, the ratio of 3.08x suggests that interest is appropriately covered, which means that lenders may be inclined to lend more money to the company, as it is seen as safe in terms of payback.Next Steps: With a high level of debt on its balance sheet, EEP could still be in a financially strong position if its cash flow also stacked up.

Simply Wall St -

Does EuroEspes SA.'s (BME:EEP) Past Performance Indicate A Stronger Future?

In this article, I will take a look at EuroEspes SA.'s (BME:EEP) most recent earnings update (30 June 2017) and compare these latest figures against its performance over the past few years, along with how the rest of EEP's industry performed. … View our latest analysis for EuroEspes Commentary On EEP's Past Performance For the purpose of this commentary, I like to use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. … Given that these values may be fairly nearsighted, I’ve estimated an annualized five-year value for EuroEspes's net income, which stands at €279.48K This shows that, on average, EuroEspes has been able to steadily improve its earnings over the past couple of years as well.

Simply Wall St -

Company Info

Description

Euroespes, S.A., a medical center, provides medical services for the prevention, diagnosis, and treatment of central nervous system disorders and other diseases in Spain and internationally. The company offers personalized and genomic medicine services for predictive, diagnostic, and therapeutic purposes. It also provides medical services, such as genomics, digital diagnosis, diagnostic imaging, neuro-psychology, neuro-ophthalmology, nursing, epigenetics, and clinical analysis services, as well as medical research services. In addition, the company offers pharmacogenetic cards; human identification cards based on genetic footprint; and a range of nutraceuticals. Euroespes, S.A. was founded in 1991 and is based in A Coruña, Spain.

Details
Name: Euroespes, S.A.
EEP
Exchange: BME
Founded: 1991
€6,701,466
10,471,041
Website: http://www.euroespes.com
Address: Euroespes, S.A.
Santa Marta de Babío s/n,
Bergondo,
A Coruña,
Galicia, 15165,
Spain
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
BME EEP Share Capital Bolsas y Mercados Espanoles ES EUR 16. Feb 2011
Number of employees
Current staff
Staff numbers
36
Euroespes employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:24
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2018/10/30
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.